LaNova Medicines Limited, a privately-held clinical-stage innovation-driven biotech specializing in ADCs and immuno-oncology, announced the initiation of its Phase 1 clinical trial of LM-299, an anti-PD-1/VEGF BsAb, in China for advanced solid tumors and the successful completion of its $42 million Series C1 financing.Founded in September 2019, LaNova's R&D engine is based on three proprietary platforms adept at tackling challenging targets and versatile modality development, which has so far enabled the in-house development of more than ten innovative programs, including monoclonal antibodies, ADCs and bispecific antibodies.Following promising preclinical results demonstrating LM-299's strong inhibition of tumor growth in hPBMCs-humanized mice and well tolerated safety profile in NHP GLP tox study, LaNova has initiated its first-in-human clinical trial in China for advanced solid tumors.

LaNova Medicines Limited是一家专注于ADC和免疫肿瘤学的私营临床阶段创新驱动生物技术公司，宣布在中国启动LM-299（一种抗PD-1/VEGF BsAb）的1期临床试验，用于晚期实体瘤，并成功完成其4200万美元的C1系列融资。LaNova的研发引擎成立于2019年9月，基于三个专有平台，擅长解决具有挑战性的目标和多功能模态开发，迄今为止，该平台已实现了十多个创新项目的内部开发，包括单克隆抗体，ADC和双特异性抗体。在NHP-GLP-tox研究中，LM-299对hPBMCs人源化小鼠肿瘤生长的强烈抑制作用以及良好的耐受性安全性得到了令人鼓舞的临床前结果，LaNova在中国首次启动了针对晚期实体瘤的人体临床试验。

LaNova is planning to initiate an additional Phase 1 clinical trial in the US and expects to submit an IND in the second half of 2024.The completed Series C1 financing was led by Sino Biopharmaceuticals and included participation from new investors Pudong Innovation Investment and Zhangjiang Haoheng, and existing investors, Qiming Venture Partners and Shanghai Healthcare Capital.

拉诺娃计划在美国启动另一项1期临床试验，并预计在2024年下半年提交IND。完成的C1系列融资由中国生物制药牵头，包括新投资者浦东创新投资和张江浩恒以及现有投资者启明创业伙伴和上海医疗保健资本的参与。

Zhong Lun Law Firm acted as the legal advisor for this round of financing.LaNova has recently initiated its Series C2 financing round.Proceeds will be primarily used to advance the clinical development of the Company's pipeline, including lead candidates:Dr. Crystal Qin, LaNova's founder, chairwoman and CEO, stated: 'Since its establishment, LaNova has been dedicated to original innovation, with a focus on the tumor microenvironment and the development of tumor-specific targeted ADCs and immune-modulating biol.

中伦律师事务所担任本轮融资的法律顾问。拉诺娃最近启动了C2系列融资回合。。